Celebrating a New Milestone-MoU Signing between Tofflon and Nova Pharma Solution

Celebrating a New Milestone-MoU Signing between Tofflon and Nova Pharma Solution!

Tofflon Group has signed a Memorandum of Understanding on the mRNA Vaccine Project in South East Asia with Nova Pharma Solutions Berhad (34608-K) at the Vaccine World Asia Congress 2024 on Nov 6.

This partnership is the beginning of an exciting collaboration between Tofflon and Nova Pharma Solution, to secure an mRNA vaccine project. Nova Pharma Solution brings expertise in engineering solutions, covering everything from pre-design and design to post-design and other supporting activities. Tofflon will work closely with Nova Pharma Solution to provide both standard and customized equipment to meet the specific process flow and technical requirements needed for the mRNA vaccine. This project will be a milestone for the Malaysia mRNA vaccine project for clinical trial purposes.

This collaboration reflects our commitment to advancing vaccine manufacturing technologies, supporting healthcare innovation, and contributing to Malaysia’s growing role in the biopharma landscape.

We look forward to working with Nova Pharma Solution on this impactful project, bringing together our shared expertise to support the development of cutting-edge mRNA technology.

Stay tuned for more updates as we embark on this exciting journey!